Senate Bill 867, signed by Governor Newsom, marks California’s first attempt to regulate AI-companion functionality built directly into children’s toys. The law prohibits any person from manufacturing, selling, exchanging, or offering for
More
Frank Ramos, a partner at Goldberg Segalla in Miami, argues that knowing how to use AI is simply not a career plan for young lawyers entering the profession today. Neither is the
More
Missouri Republicans are continuing their legal push to defend a contested electoral map, despite repeated rejections from the United States Supreme Court. The Supreme Court has consistently turned away Missouri’s attempts to
More
HSBC Holdings (LSE: HSBA) has delivered one of the most remarkable performances of any FTSE 100 stock over the past five years, rising a staggering 330% with dividends on top. The bank
More
Global equity futures retreated in early trading as investors responded to fresh concerns surrounding the artificial intelligence sector, putting pressure on major indices. The warning signs emerging from AI-related stocks have prompted
More
Investors looking to protect their portfolios should focus on companies with strong fundamentals, reliable cash flows, and durable competitive advantages that hold up during volatile periods. Market sell-offs can arrive without warning,
More
London’s benchmark FTSE 100 index fell under pressure as rising oil prices driven by US-Iran tensions continued to unsettle global markets. Crude prices remained above the $100 per barrel mark, a level
More
Andy Burnham faces mounting pressure from the hospitality industry to follow through on his pre-election support for a significant VAT reduction. More than 800 pubs, restaurants, hotels and hospitality businesses have signed
More
GSK secured FDA approval for Jideytro, known scientifically as zidesamtinib, marking the British pharmaceutical giant’s first-ever commercial lung cancer treatment. The approval came roughly two months ahead of the FDA’s original target
More
AstraZeneca (AZN) and Daiichi Sankyo are facing a significant obstacle in their push to expand the use of cancer drug Enhertu into a key new treatment setting. The two pharmaceutical giants have
More